Applied Digital Analysts Slash Their Forecasts After Q3 Results
Applied Digital Corporation (NASDAQ: APLD) reported worse-than-expected third-quarter financial results on Thursday.
These Analysts Boost Their Forecasts On Constellation Brands Following Upbeat Results
Constellation Brands Inc (NYSE: STZ) reported better-than-expected fourth-quarter financial results on Thursday.
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
CarMax Analysts Cut Their Forecasts After Downbeat Earnings
CarMax Inc (NYSE: KMX) reported weaker-than-expected fourth-quarter earnings on Thursday.
Wall Street’s Most Accurate Analysts’ Views On 3 Industrials Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Progressive Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
The Progressive Corporation (NYSE: PGR) is expected to release earnings results for its first quarter, before the opening bell on April 12, 2024.
State Street Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
State Street Corporation (NYSE: STT) is set to release earnings results for its first quarter before the opening bell on April 12, 2024.
Nike Stock Jumps On Upgrade To Buy As Analyst Says It’s ‘Time To Just Do It’
BofA analyst Lorraine Hutchinson upgraded Nike from Neutral to Buy on Thursday and raised the price target from $110 to $113, noting that "it's time to just do it."
Vertex’s Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept’s Potential Impact
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth potential, with Alpine's lead molecule poised to add over $5 billion in sales.
What’s Going On With Walker & Dunlop Shares Today?
Wedbush downgrades Walker & Dunlop to Neutral, citing concerns about rising interest rates and potential impact on transaction volumes.